60 Degrees Pharmaceuticals, Inc. (SXTP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, 60 Degrees Pharmaceuticals reported revenue of $1.0M, up 65.5% from $607,574 the year before. Net income was -$7.4M (a -732.5% net margin), or -$11.73 per diluted share. Gross margin was 22.3% and operating margin was -771.6%. Operating activities generated -$6.8M of cash, leaving -$7.0M of free cash flow. At fiscal year end, 60 Degrees Pharmaceuticals held $5.4M in total assets against $2.0M in total liabilities, including $1.5M of cash and equivalents.
Open the full interactive 60 Degrees Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
60 Degrees Pharmaceuticals Key Stats
| Share Price | $0.90 |
|---|---|
| Market Cap | $2.4M |
| Revenue YoY Growth | +65.5% |
| 52-Week Range | $0.85 – $7.20 |
| Shares Outstanding | 2.7 million (basic, 2026 Q2) |
60 Degrees Pharmaceuticals Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $253,573 | $607,574 | $1.0M |
| Gross Profit | -$220,977 | $222,809 | $223,776 |
| Operating Income | -$5.2M | -$9.7M | -$7.8M |
| Pre-Tax Income | -$3.8M | -$8.0M | -$7.4M |
| Income Tax | $250 | $250 | $0 |
| Net Income | -$3.8M | -$7.9M | -$7.4M |
| Diluted EPS | -$237.60 | -$74.20 | -$11.73 |
60 Degrees Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $437,602 | $303,385 | $162,092 | $207,898 |
| Net Income | -$2.3M | -$1.4M | -$2.1M | -$2.3M |
| Diluted EPS | -$2.64 | -$2.15 | -$1.28 | -$0.90 |
60 Degrees Pharmaceuticals Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | — | $1.7M | $1.5M |
| Current Assets | $7.2M | $5.4M | $4.9M |
| Total Assets | $7.8M | $5.8M | $5.4M |
| Current Liabilities | $2.8M | $1.7M | $1.8M |
| Total Long-Term Debt | $150,000 | $150,000 | $152,775 |
| Total Liabilities | $3.0M | $1.8M | $2.0M |
| Shareholders' Equity | $4.9M | $4.0M | $3.5M |
60 Degrees Pharmaceuticals Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$4.5M | -$5.6M | -$6.8M |
| Cash From Investing | -$115,888 | -$1.9M | $254,916 |
| Cash From Financing | $6.5M | $7.1M | $6.4M |
| Free Cash Flow | -$4.6M | -$5.8M | -$7.0M |
Figures from 60 Degrees Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full 60 Degrees Pharmaceuticals financials page for every line item.
60 Degrees Pharmaceuticals Company Profile
| Ticker | SXTP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Washington, District of Columbia |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001946563 |
Frequently Asked Questions
What was 60 Degrees Pharmaceuticals' revenue in fiscal 2025?
60 Degrees Pharmaceuticals (SXTP) reported revenue of $1.0M for fiscal 2025.
What is 60 Degrees Pharmaceuticals' annual revenue history?
60 Degrees Pharmaceuticals' annual revenue by fiscal year: 2023: $253,573; 2024: $607,574; 2025: $1.0M.
What was 60 Degrees Pharmaceuticals' net income in fiscal 2025?
60 Degrees Pharmaceuticals reported net income of -$7.4M for fiscal 2025.
What was 60 Degrees Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
60 Degrees Pharmaceuticals' diluted EPS was -$11.73 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did 60 Degrees Pharmaceuticals generate in fiscal 2025?
60 Degrees Pharmaceuticals generated -$7.0M of free cash flow in fiscal 2025.
What was 60 Degrees Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), 60 Degrees Pharmaceuticals reported revenue of $207,898.
How much debt does 60 Degrees Pharmaceuticals have?
60 Degrees Pharmaceuticals reported $152,775 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of 60 Degrees Pharmaceuticals are outstanding?
60 Degrees Pharmaceuticals reported a weighted average of 2.7 million basic shares outstanding in 2026 Q2.
What is 60 Degrees Pharmaceuticals' market cap?
Based on its latest closing price, 60 Degrees Pharmaceuticals (SXTP) has a market capitalization of about $2.4M.
When does 60 Degrees Pharmaceuticals' fiscal year end?
60 Degrees Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is 60 Degrees Pharmaceuticals headquartered?
60 Degrees Pharmaceuticals lists its business address in Washington, District of Columbia in its SEC filings.